Proteostasis Therapeutics Inc (PTI.OQ)
5.12USD
20 Apr 2018
$0.05 (+0.99%)
$5.07
$5.05
$5.21
$4.97
176,085
501,563
$8.61
$1.41
Latest Key Developments (Source: Significant Developments)
Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share
Dec 13 (Reuters) - Proteostasis Therapeutics Inc
Proteostasis Therapeutics To Sell 7 Mln Shares In Public Offering
Dec 12 (Reuters) - Proteostasis Therapeutics Inc
Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies
Dec 11 (Reuters) - Proteostasis Therapeutics Inc
Proteostasis Therapeutics Q3 loss per share $0.56
Nov 14 (Reuters) - Proteostasis Therapeutics Inc
Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
Oct 31 (Reuters) - Proteostasis Therapeutics Inc
Proteostasis Therapeutics files to say it is offering 4.3 mln shares of its common stock
Proteostasis Therapeutics Inc
Proteostasis Therapeutics files for common stock offering
Proteostasis Therapeutics Inc
Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration
Proteostasis Therapeutics Inc
Proteostasis Therapeutics says appointment of James M. Detore as CFO
Proteostasis Therapeutics Inc
BRIEF-Proteostasis Receives Endorsement From Cystic Fibrosis Foundation For Study Of PTI-428 In CF Subjects On Background Symdeko Therapy
* PROTEOSTASIS RECEIVES ENDORSEMENT FROM THE CYSTIC FIBROSIS FOUNDATION'S THERAPEUTIC DEVELOPMENT NETWORK FOR THE STUDY OF THE COMPANY'S AMPLIFIER, PTI-428, IN CF SUBJECTS ON BACKGROUND SYMDEKO™ THERAPY Source text for Eikon: Further company coverage: